ATE444760T1 - Glutathion zur behandlung von influenzainfektionen - Google Patents

Glutathion zur behandlung von influenzainfektionen

Info

Publication number
ATE444760T1
ATE444760T1 AT98902446T AT98902446T ATE444760T1 AT E444760 T1 ATE444760 T1 AT E444760T1 AT 98902446 T AT98902446 T AT 98902446T AT 98902446 T AT98902446 T AT 98902446T AT E444760 T1 ATE444760 T1 AT E444760T1
Authority
AT
Austria
Prior art keywords
glutathione
treatment
infections
influence
influenza virus
Prior art date
Application number
AT98902446T
Other languages
English (en)
Inventor
Dean Jones
Satoru Furukawa
Original Assignee
Univ Emory
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Kyowa Hakko Kogyo Kk filed Critical Univ Emory
Application granted granted Critical
Publication of ATE444760T1 publication Critical patent/ATE444760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98902446T 1997-01-13 1998-01-12 Glutathion zur behandlung von influenzainfektionen ATE444760T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3449697P 1997-01-13 1997-01-13
US3508797P 1997-01-13 1997-01-13
US3541797P 1997-01-13 1997-01-13
US3508897P 1997-01-13 1997-01-13
PCT/US1998/000380 WO1998030228A1 (en) 1997-01-13 1998-01-12 Compounds and their combinations for the treatment of influenza infection

Publications (1)

Publication Number Publication Date
ATE444760T1 true ATE444760T1 (de) 2009-10-15

Family

ID=27488222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98902446T ATE444760T1 (de) 1997-01-13 1998-01-12 Glutathion zur behandlung von influenzainfektionen

Country Status (8)

Country Link
US (2) US6013632A (de)
EP (1) EP1007077B1 (de)
JP (1) JP4578578B2 (de)
AT (1) ATE444760T1 (de)
AU (1) AU5910998A (de)
CA (1) CA2277911C (de)
DE (1) DE69841217D1 (de)
WO (1) WO1998030228A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US8507018B2 (en) * 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
AU5142699A (en) 1998-07-31 2000-02-28 Mount Sinai Hospital Corporation Methods and compositions for increasing insulin sensitivity
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
IT1312377B1 (it) * 1999-03-05 2002-04-15 Uni Ci S R L Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
WO2000072862A1 (en) 1999-06-01 2000-12-07 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
US6187332B1 (en) * 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
CA2394211A1 (en) * 1999-12-15 2001-06-21 Kyowa Hakko Kogyo Co., Ltd. Stabilizers for sodium l-ascorbate-2-phosphate
US6180144B1 (en) * 2000-01-27 2001-01-30 The Goodyear Tire & Rubber Co Chewing gum base stabilized with carnosic acid
JP3988014B2 (ja) * 2000-02-02 2007-10-10 味の素株式会社 ウイルス感染症予防剤
EP1145719A3 (de) * 2000-03-10 2001-11-14 Pfizer Products Inc. Verwendung von einem Ferrosalz zur Hemmung des oxidativen Abbaus von pharmazeutischen Zusammensetzungen
CA2416899C (en) 2000-07-28 2010-10-12 Immupharm Aps Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
IT1320080B1 (it) 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
SE0003907D0 (sv) * 2000-10-27 2000-10-27 Swe Dencare Komposition för eliminering av tandsten ur munnen
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
WO2002041837A2 (en) * 2000-11-22 2002-05-30 Rxkinetix, Inc. Treatment of mucositis
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
JP3957195B2 (ja) * 2001-01-24 2007-08-15 ブライトスマイル プロフェッショナル インク． 局所用口腔ケア組成物
WO2002078717A2 (en) * 2001-03-28 2002-10-10 Societe Des Produits Nestle S.A. Compositions and methods for reducing rna virus pathogenicity
CN1537009A (zh) * 2001-04-25 2004-10-13 �ư������������޹�˾ 一种用于治疗或者预防个体功能性维生素b12缺陷的方法以及在该方法中使用的药物组合物
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US6929800B2 (en) * 2001-08-06 2005-08-16 Abdul Rasoul Salman Nasal passage cleaning composition
CA2357053A1 (en) * 2001-09-04 2003-03-04 Unknown Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
US7767714B2 (en) 2002-02-18 2010-08-03 Ajinomoto Co., Inc. Method of preventing infectious diseases
US8679462B2 (en) * 2002-04-11 2014-03-25 Saeed Rezakhany Methods of preventing respiratory infections
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
ES2542985T3 (es) 2003-07-22 2015-08-13 Kyowa Hakko Bio Co., Ltd Composición preventiva o terapéutica para una enfermedad infecciosa vírica
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
US20050112158A1 (en) * 2003-11-17 2005-05-26 Clariant Internatinonal, Ltd. Method for synthesis of silylated ascorbic acid derivatives
WO2007000662A2 (en) * 2005-02-03 2007-01-04 Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
CA2598792A1 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US20070077258A1 (en) * 2005-03-29 2007-04-05 Guilford F T ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS
US20100040558A1 (en) * 2005-04-26 2010-02-18 University Of South Florida Green tea polyphenol alpha secretase enhancers and methods of use
US20070009443A1 (en) * 2005-07-05 2007-01-11 Hensley Charles B Method for inhibiting occupation by rhinovirus of cell in the nasal membrane
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
WO2007064755A2 (en) * 2005-11-30 2007-06-07 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
US20080014277A1 (en) * 2006-07-14 2008-01-17 Insight Pharmaceuticals Llc Reduced-odor thiol compositions
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
JP4300370B2 (ja) * 2007-03-13 2009-07-22 春三 小林 上皮改善剤
US8796206B2 (en) * 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2009128523A1 (ja) 2008-04-17 2009-10-22 味の素株式会社 免疫賦活剤
DE102009003974A1 (de) * 2009-01-07 2010-07-15 Medphano Arzneimittel Gmbh Verfahren zur Erhöhung der Widerstandsfähigkeit gegen Influenza-Infektionen mittels Vitamin-K1-Tropfen (KA-VIT-Tropfen)
ES2592202T3 (es) 2009-04-28 2016-11-28 Wm. Wrigley Jr. Company Composiciones orales para beneficios cutáneos
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2011080593A2 (en) * 2009-12-30 2011-07-07 Purapharm International (Hk) Limited Materials and methods for prevention and treatment of viral infections
IT1401504B1 (it) 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato
IT1405758B1 (it) * 2010-11-03 2014-01-24 Stewart Italia Srl Preparazione farmaceutica a base nac in soluzione ipertonica per il trattamento di affezioni rinofaringee
WO2012136851A1 (en) * 2011-04-08 2012-10-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
JP6138048B2 (ja) * 2011-10-12 2017-06-07 フォーデイズ株式会社 システインペプチド含有健康飲料
US8916179B2 (en) 2011-10-25 2014-12-23 T.F.H. Publications, Inc. Ascophyllum nodosum animal chews
KR101725101B1 (ko) * 2015-03-20 2017-04-11 주식회사 비에이치랩 글루타치온을 함유하는 미백용 피부 외용제 조성물 및 이의 제조 방법
FR3058640B1 (fr) * 2016-11-14 2020-06-19 Robert Vachy Composes pour leur utilisation dans le traitement de la grippe
WO2018204394A1 (en) * 2017-05-02 2018-11-08 The Proimmune Company L.L.C. Compositions and methods for the treatment of zika viral diseases
RU2659161C1 (ru) * 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
AU2021262136A1 (en) * 2020-05-01 2022-12-08 MUCPharm Pty Ltd Preventing and treating viral infections
WO2021235494A1 (ja) * 2020-05-20 2021-11-25 孝章 赤池 活性硫黄化合物を主成分とする薬剤
WO2021236958A1 (en) * 2020-05-22 2021-11-25 Auro Pharmaceuticals, Inc. Compositions and methods of treatment with glutathione
WO2022011305A2 (en) * 2020-07-09 2022-01-13 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184505A (en) * 1962-06-18 1965-05-18 Mead Johnson & Co Process for the n-monoacylation of cysteine
GB1125675A (en) * 1966-02-10 1968-08-28 Kyowa Hakko Kogyo Kk Stable ascorbic acid composition and process for preparing the same
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
DE2509531A1 (de) * 1975-03-05 1976-09-16 Thomae Gmbh Dr K Antivirales mittel
RO79426B1 (ro) * 1982-02-23 1984-07-30 Romulus Constantin Dinu Compozitie medicamentoasa pentru tratamentul unor neuroviroze
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS59231016A (ja) * 1983-06-13 1984-12-25 Suntory Ltd 安全なビタミンｃ製剤
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3728917A1 (de) * 1987-08-29 1989-03-09 Roth Hermann J Neue lipide mit unsymmetrisch substituierter disulfidbruecke
US5212079A (en) * 1987-10-08 1993-05-18 Kyowa Hakko Kogyo Kabushiki Kaisha Process for the preparation of ascorbic acid-2-phosphate
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JP2926412B2 (ja) * 1989-05-19 1999-07-28 株式会社林原生物化学研究所 α―グリコシル―Ｌ―アスコルビン酸とその製造方法並びに用途
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
US5238683A (en) * 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
US5135730A (en) * 1990-03-28 1992-08-04 Kabushiki Kaisha Kobe Seiko Sho Method and apparatus for synthesizing diamond by combustion
JPH0427356A (ja) * 1990-05-22 1992-01-30 Yoshie Kurihara 味覚修飾組成物及び味覚修飾物質の安定化方法
JP3122663B2 (ja) * 1990-06-21 2001-01-09 協和醗酵工業株式会社 アスコルビン酸―２―リン酸の製造法
JP2749186B2 (ja) * 1990-08-16 1998-05-13 ハウス食品株式会社 イチゴ染色剤及びイチゴの染色方法
US5464825A (en) * 1991-03-14 1995-11-07 Cornell Research Foundation, Inc. Raising glutathione equivalent levels using N-acyl glutathione monoesters
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
EP0535390B1 (de) * 1991-09-30 1996-05-15 Transcend Therapeutics, Inc. Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US5492689A (en) * 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
JPH06199697A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 抗ウイルス・抗菌・殺菌剤
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
JPH08502288A (ja) * 1992-10-09 1996-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー 感昌症状を治療するための医薬組成物及び用法
US5463029A (en) * 1992-11-23 1995-10-31 Immunex Corporation Purification of fusion proteins comprising GM-CSF and IL-3
AU5040493A (en) * 1992-11-30 1994-06-09 Transcend Therapeutics, Inc Method for treating systemic inflammatory response syndrome
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
FR2708288B1 (fr) * 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
US5432274A (en) * 1993-07-28 1995-07-11 National Research Council Of Canada Redox dye and method of preparation thereof using 2-hydroxypropyl-β-cyclodextrin and 1,1'-dimethylferrocene
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
BR9407414A (pt) * 1993-09-07 1996-11-12 Procter & Gamble Composições contendo um sal de aminoácido de agente antiinflamatório não-esteroide de ácido propiônico e pelo menos um descongestionante um expectorante um anti-histamina e um antitussivo
US5516921A (en) * 1994-01-27 1996-05-14 Ariad Pharmaceuticals, Inc. Thiono-lactone inhibitors of protein trafficking and uses therefor
JPH0838065A (ja) * 1994-08-03 1996-02-13 Nichimo Co Ltd 魚類用抗ウイルス症剤
DE4431175A1 (de) * 1994-09-01 1996-04-11 Medico Pharma Vertriebs Gmbh Neue, Chelatbildner enthaltende Arzneimittel
GB9502489D0 (en) * 1995-02-09 1995-03-29 Animal Health Trust Expression of the non-structural protein NS1 of influenza virus and detection of anti-NS1 antibody in serum

Also Published As

Publication number Publication date
EP1007077B1 (de) 2009-10-07
EP1007077A1 (de) 2000-06-14
US6107281A (en) 2000-08-22
EP1007077A4 (de) 2003-07-23
AU5910998A (en) 1998-08-03
US6013632A (en) 2000-01-11
JP4578578B2 (ja) 2010-11-10
JP2001511770A (ja) 2001-08-14
CA2277911A1 (en) 1998-07-16
WO1998030228A1 (en) 1998-07-16
DE69841217D1 (de) 2009-11-19
CA2277911C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
ATE444760T1 (de) Glutathion zur behandlung von influenzainfektionen
ATE271041T1 (de) Analoga von duocarmycin and cc-1065
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
WO1998030228B1 (en) Compounds and their combinations for the treatment of influenza infection
BR0113666A (pt) Inibidores da protease peptidomimética
EA200000840A1 (ru) Антивирусные производные пиримидина
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
DE60024100D1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
DE69938935D1 (de) Zyklische conotoxin-peptide
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
TR199900211T2 (xx) Mupirosin ve klorheksidin'den olu�an bile�im.
ATE270667T1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
ES2170251T3 (es) (s)-hidroxinitriloliasa de hevea brasiliensis.
DE69616074D1 (de) Ara-c derivate
ATE251910T1 (de) Zusammensetzungen zur modulierung der immunantwort und zur behandlung entzündlicher krankheiten
ATE253936T1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
ATE189460T1 (de) Gegen protozoen wirksamezyklische tetrapeptide
DE60033783D1 (de) Regulatorische/entfaltende peptide von ezrin
ATE255594T1 (de) Hepatitis b inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties